Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)

Next Previous
X
Search
Trial Profile

A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PR 006 (Primary) ; Methylprednisolone; Prednisone; Rituximab; Sirolimus
  • Indications Dementia; Frontotemporal dementia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms PROCLAIM
  • Sponsors Prevail Therapeutics

    • Most Recent Events

    • 21 Feb 2024 Planned number of patients changed from 23 to 35.
    • 15 Sep 2023 Planned number of patients changed from 15 to 23.
    • 15 Sep 2023 Planned End Date changed from 1 Dec 2027 to 31 Aug 2029.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top